Benitec reports durable improvements in swallowing function with BB-301 in OPMD interim results

Benitec Biopharma Inc.

Three subjects treated with low-dose BB-301 showed significant, clinically meaningful improvements in swallowing function at 12 months (Subjects 1,2) and 3 months (Subject 3) post-treatment.
Subject 1: 41% reduction in SSQ total symptom burden at 12 months; VFSS showed reductions in pharyngeal residue across all food and liquid consistencies.
Subjects 2 and 3: near-complete resolution of pathologic sequential swallows; Subject 2 achieved clinically normal SSQ (68 units) at 12 months, Subject 3 at 3 months (70 units).
No severe adverse events reported; five subjects safely treated; sixth and final Cohort 1 subject expected to receive low-dose BB-301 in Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.